Evidence map›Paper›PMID 40927994›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2025

Tribenzoylarsine - A Benign Arsenic Precursor for InAs Nanocrystals.

Artsiom Antanovich, Volodymyr Shamraienko, Jannika Lauth, Vladimir Lesnyak

Abstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Large Colloidal InAs Nanocrystals Synthesized with a Grignard Reagent.Chemistry of materials : a publication of the American Chemical Society · 2026
    Article
  2. Tribenzoylarsine - A Benign Arsenic Precursor for InAs Nanocrystals.Small (Weinheim an der Bergstrasse, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Artsiom AntanovichInstitute of Physical Chemistry and Electrochemistry, Leibniz University Hannover, Callinstraße 3a, 30167, Hannover, Germany.ORCID https://orcid.org/0000-0001-8533-7347
Volodymyr ShamraienkoPhysical Chemistry, TU Dresden, Zellescher Weg 19, 01069, Dresden, Germany.
Jannika LauthInstitute of Physical Chemistry and Electrochemistry, Leibniz University Hannover, Callinstraße 3a, 30167, Hannover, Germany.ORCID https://orcid.org/0000-0002-6054-9615
Vladimir LesnyakPhysical Chemistry, TU Dresden, Zellescher Weg 19, 01069, Dresden, Germany.ORCID https://orcid.org/0000-0002-2480-8755

Funding

Deutsche Forschungsgemeinschaft 417590517Deutsche Forschungsgemeinschaft SFB-1415H2020 Marie Skłodowska-Curie Actions 101031243Niedersächsische Ministerium für Wissenschaft und Kultur Stay-3/22-7633/2022
6 · The paper itself

Abstract

III-V semiconductor nanocrystals (NCs) have emerged as a benign alternative to II-VI and IV-VI NCs, which are restricted due to the toxicity of the comprising elements. While InP NCs advanced significantly, the development of infrared-emitting InAs NCs has been relatively slow-paced. This is due to the synthetic challenges arising from the highly covalent bonding in InAs and the limited range of available arsenic sources. Most importantly, current syntheses rely on hazardous pyrophoric and costly reagents, which hampers their wider adoption. In this work, the synthesis of tribenzoylarsine is reported, which can be used as a novel nonvolatile, nonpyrophoric, and hence safer precursor for metal arsenide nanoparticles. Tribenzoylarsine reacts with indium oleate without additional reducing agents yielding small (≈2 nm) InAs NCs. By tuning synthesis parameters (e.g., the addition of zinc oleate or using continuous injection) it is possible to cover the photoluminescence range of 630-780 nm with full width at half maximum as low as 170-210 meV, which is a very competitive value to the existing synthetic approaches. Along with the significantly safer nature of tribenzoylarsine and the great potential for synthesis optimization, this makes it a very promising alternative to the currently used arsenic precursors.

Indexed as

acylarsineindium arsenidephotoluminescencequantum dots

Identifiers

PMID40927994
PMCPMC12547999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.